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Abstract
Purpose Deoxycytidine kinase (dCK) is a rate-limiting
enzyme in deoxyribonucleoside salvage, a metabolic
pathway involved in the production and maintenance of a
balanced pool of deoxyribonucleoside triphosphates
(dNTPs) for DNA synthesis. dCK phosphorylates and
therefore activates nucleoside analogs such as cytarabine,
gemcitabine, decitabine, cladribine, and clofarabine that are
used routinely in cancer therapy. Imaging probes that target
dCK might allow stratifying patients into likely responders
and nonresponders with dCK-dependent prodrugs. Here we
present the biodistribution and radiation dosimetry of three
fluorinated dCK substrates,
18F-FAC, L-
18F-FAC, and
L-
18F-FMAC, developed for positron emission tomography
(PET) imaging of dCK activity in vivo.
Methods PET studies were performed in nine healthy
human volunteers, three for each probe. After a transmis-
sion scan, the radiopharmaceutical was injected intrave-
nously and three sequential emission scans acquired from
the base of the skull to mid-thigh. Regions of interest
encompassing visible organs were drawn on the first PET
scan and copied to the subsequent scans. Activity in target
organs was determined and absorbed dose estimated with
OLINDA/EXM. The standardized uptake value was calcu-
lated for various organs at different times.
Results Renal excretion was common to all three probes.
Bone marrow had higher uptake for L-
18F-FAC and L-
18F-
FMAC than
18F-FAC. Prominent liver uptake was seen in
L-
18F-FMAC and L-
18F-FAC, whereas splenic activity was
highest for
18F-FAC. Muscle uptake was also highest for
18F-FAC. The critical organ was the bladder wall for all
three probes. The effective dose was 0.00524, 0.00755, and
0.00910 mSv/MBq for
18F-FAC, L-
18F-FAC, and L-
18F-
FMAC, respectively.
Conclusion The biodistribution of
18F-FAC, L-
18F-FAC,
and L-
18F-FMAC in humans reveals similarities and differ-
ences. Differences may be explained by different probe
affinities for nucleoside transporters, dCK, and catabolic
enzymes such as cytidine deaminase (CDA). Dosimetry
demonstrates that all three probes can be used safely to
image the deoxyribonucleoside salvage pathway in humans.
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Positron emission tomography (PET) and PET/CT imaging
using the glucose analog
18F-fluorodeoxyglucose (FDG) are
increasingly used to monitor the effects of cancer therapies.
Treatment responders determined by FDG PET/CT have
better overall survival rates than nonresponders [1]. However,
cancer mortality, with few notable exceptions, has remained
high implying that treatment response rates have not
increased significantly [2]. One reason for the low response
rates is the inability to measure molecular determinants of
response that would allow clinicians to stratify cancer
patients and therefore apply the most appropriate treatments.
Deoxycytidine kinase (dCK) is an attractive imaging and
therapeutic target. dCK is a key enzyme in deoxyribonu-
cleoside salvage, a biosynthetic pathway involved in
production and maintenance of a balanced pool of
deoxyribonucleoside triphosphates (dNTPs) for DNA syn-
thesis (reviewed in [3]). dCK is highly expressed in
hematopoietic/lymphoid cells, in lymphoid malignancies,
a n di ns o m es o l i dt u m o r s( r e v i e w e di n[ 3]). Several
prodrugs routinely used in cancer therapy such as cytar-
abine, gemcitabine [4, 5], decitabine, cladribine, and
clofarabine [6] (Fig. 1a, b) require phosphorylation by
dCK for their pharmacodynamic effects. As of November
2009 more than 1,000 clinical trials evaluating responses to
such prodrugs were ongoing (Fig. 1b). However, response
rates to these prodrugs are generally low, ranging from 5 to
30% and side effects can be severe. It would therefore be
highly desirable to identify patients who are more likely to
respond to treatment with these nucleoside analogs prior to
therapy. This is, however, currently impossible.
Previously, we described the synthesis of the deoxycyti-
dine analog
18F-1-(2′-deoxy-2′-fluoro-arabinofuranosyl)cyto-
sine (
18F-FAC) [7]. In subsequent work we showed that
18F-
FAC is a high affinity substrate for dCK [8]; this substrate is
phosphorylated and trapped in tissues by this rate-limiting
enzyme in the deoxyribonucleoside salvage pathway.
18F-
FAC and dCK-dependent prodrugs share the same biochem-
ical pathway in cancer cells (Fig. 1a). Thus,
18F-FAC PET
may enable stratification of patients into likely responders
versus poor or nonresponders to these prodrugs.
Deamination is one of the most important resistance
mechanisms that explain the low response rates to some of
the dCK-dependent prodrugs. Cytarabine, gemcitabine, and
decitabine undergo extensive deamination in vivo by
cytidine deaminase (CDA), an enzyme that is expressed at
high levels in normal tissues and can be upregulated in
tumors [9]. Deamination converts these prodrugs to inactive
analogs. To circumvent the deamination problem, and thus
increase drug effectiveness, purine nucleoside analogs such
as cladribine and clofarabine have been developed [10].
Analogous to cytarabine, gemcitabine, and decitabine,
18F-
FAC also undergoes deamination by CDA [11]. Deamina-
tion by CDA may affect the specificity of the PET dCK
assay by producing a metabolite of
18F-FAC that is not a
substrate for dCK and thus may confound dCK imaging.
Data in mice show that as early as 1 min after i.v. injection,
~14% of
18F-FAC has been deaminated, and at 30 min post-
injection, the vast majority (~90%) of
18F-FAC has
undergone deamination [11]. Deamination is likely to be
even faster in humans, who express significantly more
deaminase activity than mice [12].
To overcome the deamination problem and increase the
metabolic stability of the probe, we have produced a series
of deoxycytidine analogs that have high affinity for dCK,
but are not susceptible to deamination. The rationale for
developing these second-generation dCK-specific probes
was that while dCK lacks stereospecificity and acts on both
D- (natural) and L- (non-natural) substrate enantiomers [13],
CDA is stereospecific and preferentially acts on natural
nucleosides in the D-chiral conformation [13]. The produc-
tion and preclinical characterization of radiolabeled L-
enantiomers of
18F-FAC are described elsewhere [11]. In
this study we present the human biodistribution and
radiation dosimetry of
18F-FAC and of two non-natural
deoxycytidine analogs, L-
18F-FAC [1-(2′-deoxy-2′-
18F-flu-
oro-arabinofuranosyl)cytosine] and L-
18F-FMAC (2′-de-
oxy-2′-
18F-fluoro-5-methyl-beta-L-arabinofuranosylcyto-
sine). We also present initial PET images obtained with
18F-
FAC in a patient with lymphoma and with L-
18F-FMAC in
a patient with metastatic ovarian cancer.
Materials and methods
Probes
Radiochemical synthesis, chemical and radiochemical
quality control, i.e., radionuclide analysis, GC analysis for
residual solvents, the test for Kryptofix, the test for pH, and
the sterility and pyrogenicity tests, are described in the
“Supplementary methods” section.
Human subjects
The study protocol was approved by the Institutional Review
Board for Human Subjects at UCLA, the UCLA Medical
Radiation Safety Committee, and the Radioactive Drug
Research Committee (RDRC) of the US Food and Drug
Administration (FDA). All human subjects provided written
informed consent following a thorough explanation of the
study by a qualified physician. Nine healthy volunteers (four
women and five men with a median age of 26 years; range
21–34 years), one lymphoma patient, and one ovarian cancer
patient were enrolled.
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All volunteers fasted for at least 4 h before administration
of the radiopharmaceutical. A whole-body ECAT/EXACT
HR+positron emission tomograph (CTI/Siemens, Knox-
ville, TN, USA) was utilized [14]. The administered
activity for each radiopharmaceutical was based on dosim-
etry studies in mice; the maximum allowed activity by the
RDRC for
18F-FAC was 407 MBq (11 mCi), for L-
18F-FAC
204 MBq (5.5 mCi), and for L-
18F-FMAC 122 MBq
(3.3 mCi). Probe toxicity was ruled out in rats by necropsy
after injecting the cold analogs at 100-fold higher concen-
trations than the radiolabeled analogs.
18F-FAC was
injected at an activity of 304±86 MBq (median 263; range
247–403 MBq), L-
18F-FAC at 188±5 MBq (median 185;
range 185.0–193.5 MBq), and L-
18F-FMAC at 107±2 MBq
(median 106; range 105–108 MBq), respectively.
The PET imaging protocol consisted of a transmission
scan and three emission scans (from base skull to mid-
thigh) starting at approximately 21, 48, and 77 min after
intravenous tracer administration. Emission scan and
transmission scan duration was 4 min per bed position for
a total of six or seven bed positions, depending on the
height of the volunteer.
Image reconstruction
PET images were reconstructed using an iterative algorithm
(ordered subset expectation maximization, 2 iterations,
8 subsets). A 6-mm Gaussian smooth was applied post
reconstruction. The reconstructed axial slices were assem-
bled into a volume set of the upper body, from which
coronal and sagittal planes could be extracted.
Dosimetry
The Medical Internal Radiation Dose (MIRD) schema was
followed for the calculation of the absorbed dose [15]. The
Fig. 1 a The dCK-dependent nucleoside analog prodrug gemcitabine
(dFdC) and
18F-FAC analogs share a common transport (ENT1) and
phosphorylation (dCK) mechanism. Both gemcitabine and
18F-FAC
are subject to deamination by cytidine deaminase (CDA). 5′-NT 5′-
nucleotidase, MP monophosphate, TP triphosphate. b FDA-approved
drugs that require dCK for their pharmacodynamic effects and the
time line of their approval. Note the diversity of the chemical
structures of these drugs, indicating the ability of dCK to phosphor-
ylate both pyrimidine and purine analogs
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description. The OLINDA/EXM (Organ Level Internal
Dose Assessment Code, Vanderbilt University, 2003)
program was used to estimate the absorbed dose [16]. All
significant emissions for
18F were used in the computations.
Organ absorbed doses are determined by integration of all
source-target combinations using standardized human
phantoms; here we used the adult male or adult female.
Regions of interest were placed using a 50% isocontour
of an organ on the first volume set of the body and included
the entire organ. The regions were copied to the later
acquired scans and activity concentration determined. For
the urinary bladder, a 25% isocontour was used. Organ
volumes for each volunteer were assumed to be constant
over time, i.e., the same on each scan, with the exception of
the bladder, for which the actual volume was determined on
every scan.
Organ activity concentration was measured at different
time points and was not decay corrected. Organ mass was
estimated to be a fraction of body weight as given in Table
A.1 on p. 15 of ICRP publication 53 [17] and by OLINDA/
EXM [16]. Measured activity concentration multiplied by
organ mass yields total organ activity, i.e., accumulated
activity at a specific time point. Organ activity was
measured as a function of time.
Regions were drawn over the heart, kidneys, liver,
marrow (spine), muscles (deltoid and trapezius), salivary
glands, spleen, and urinary bladder. The scans did not
include the upper part of the head. Since the probes do not
cross the blood-brain barrier, cerebral uptake does not
contribute to internally absorbed dose. No scans of the
lower extremities were obtained; activity concentration for
muscle and bone marrow were measured in the upper body
and assumed to be the same for the legs. The entire bone
marrow and muscle mass was included to calculate
accumulated activity.
For most organs the probe uptake is rapid, and
instantaneous uptake was assumed for our calculations.
This initial uptake was obtained by extrapolation of the
measured organ activity to the zero time point by assuming
a linear function. This corresponds to Fig. 5 on p. 11 of the
MIRD primer for absorbed dose calculations [15]. After the
last measured point it was assumed that the activity
remained in the organ and decayed with the physical half-
life of
18F. For the bladder a different time-activity curve
was hypothesized. At time zero the bladder activity is zero,
which increased linearly to the first measured time point.
After the last time point, it was assumed that bladder
contents remained the same with physical decay only. The
measured organ curves were supplemented with the
assumed early instantaneous uptake (linear increase for
the urinary bladder; see MIRD primer Fig. 3 on p. 10 [15])
and hypothesized late decay, and interpolated over equidis-
tant time intervals (see “Appendix” Fig. A1). Numerical
integration provided the area under the curve (see “Appen-
dix” Fig. A2; MIRD primer Fig. 6 p. 12 [15]). Dividing this
area under the curve, i.e., accumulated activity [15] or time-
integrated activity (MIRD pamphlet 21 [18]), by the
administered activity yields the residence time. The
remainder of the body was estimated by subtracting the
activity in the organs from the total body. The residence
times were entered into OLINDA/EXM and the absorbed
doses calculated. Absorbed doses were estimated for each
volunteer separately. After applying the tissue weighting
factors from ICRP publication 103 to the equivalent dose
for each organ, the effective dose was obtained [19].
Gender averaging yielded the effective dose E for the
reference person as explained in Fig. B.3 of ICRP
publication 103 (p. 274) [19] (see “Appendix”).
The assumption that all activity remained and decayed
inside the organs after the last measured point is a
conservative approach and may be considered as a
“worst-case scenario.” However, we did not aim for precise
dosimetry, but conducted this study to ascertain that we
were within RDRC limits for absorbed doses in human
research.
Biodistribution
The activity concentration was decay corrected to the time
of injection, so that the standardized uptake value (SUV)
could be calculated. SUV is defined as: average organ
activity in Bq/ml divided by average body activity (i.e.,
administered activity divided by body weight) in Bq/kg. A
tissue density of 1 was assumed so that 1 ml corresponds to
1 g and the SUV becomes dimensionless. The SUV for
several target tissues was computed for each time point.
The biodistribution was visualized by creating maximum
intensity projection images for rapid inspection.
For an in-depth discussion of SUVas a parameter having
a “dimension” or being a simple ratio, the reader is referred
to the Appendix of reference [20].
Results
A representative scan for each probe is given in Fig. 2
showing the highest activity in the bladder. Organ activity
as a function of time was analyzed and biological half-life
calculated using an exponential fit; the results are given in
Table 1. Splenic uptake was high for
18F-FAC but low for
L-
18F-FAC and L-
18F-FMAC (Fig. 2). Some organs, such as
muscle and liver, exhibited an actual increase in tracer
uptake from 50 to 80 min after injection (indicated with a
positive sign in Table 1). The vast majority of biological
half-lives were longer than the physical half-life of
18F.
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expected, the activity increased with time. Of the nine
volunteers, only three reached the maximum bladder uptake
within 75 min. The other six had the maximum concentration
on their third scan and the timing of the true maximum
remains unknown. We assumed that the activity stayed within
the bladder after the last measured time point and decayed
completely with the physical half-life.
Dosimetry
The residence time τ was calculated for each probe and every
volunteer by measuring the accumulated activity per organ
and dividing it by the administered activity (see “Appendix”).
The average τ per probe is given in Table 2 for various
organs and the remainder of the body. The τs were the input
for the OLINDA/EXM program, which then calculated the
absorbed dose for each subject in the target organs. The
critical organ (i.e., receiving the highest absorbed dose) for
every probe was the bladder. Table 3 shows the highest
absorbed dose per organ (i.e., the worst-case volunteer) for
the particular probe. Administering an activity of 400 MBq
would furnish an absorbed dose of 27 mGy to the bladder for
L-
18F-FMAC. This worst-case scenario of no voiding is still
within the allowed limit of 50 mSv (see “Appendix”).
Average absorbed dose is shown in Table 4 for various
organs and tissues. The organ receiving the highest
absorbed dose was the bladder wall for all three probes.
The spleen (for
18F-FAC) and the liver (for L-
18F-FAC and
L-
18F-FMAC) were second and the kidneys third (for all
three probes).
The effective dose for the reference person as defined in
ICRP publication 103 [19] (see “Appendix”) is shown in
Table 5. An administered activity of 400 MBq would result
in an effective dose of 2.1±0.3, 3.0±0.5, and 3.6±0.7 mSv
for
18F-FAC, L-
18F-FAC, and L-
18F-FMAC, respectively.
These values are well below the limit of 30 mSv as
established in 21CFR361.1 [21] and applied by our RDRC
for research in human subjects.
Biodistribution
The distribution of
18F-FAC, L-
18F-FAC, and L-
18F-FMAC
in the upper body of a typical healthy volunteer is shown in
Fig. 2. High uptake in the bladder and kidneys was
common to all three probes. Bone marrow was visualized
Fig. 2 Projection images obtained in three healthy volunteers using
different FAC analogs. Organs are indicated by arrows (B bone
marrow, Bl bladder, K kidney, L liver, M myocardium, S spleen, SG
salivary gland). Note the high splenic uptake for
18F-FAC while
hepatic uptake was highest for L-
18F-FAC and L-
18F-FMAC. Bone
marrow was visualized with all three tracers; marked tracer clearance
is seen from kidneys into the bladder. The images are scaled to the
maximum liver uptake, i.e., SUV 1.7 for the left panel, SUV 6.8 for
the middle panel, and SUV 4.9 for the right panel; this permits direct
comparison
Table 1 Biological half-life in minutes for specific organs and probes.
Mean±1 SD of three volunteers per probe
Organ
18F-FAC L-
18F-FAC L-
18F-FMAC
Heart −211±4 −292±94 −616±384
Kidneys −107±9 −187±158 −112±68
Liver −221±24 +516±370 +607±30
Marrow −560±99 −733±99 −666±143
Muscle +317±155 +918±1,853 +3,900±2,473
Salivary glands −144±27 −340±325 +911±178
Spleen −114±17 −343±281 −359±54
A plus sign indicates increasing uptake and a minus sign decreasing
uptake with time
Urinary bladder is not measurable
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18F-FAC. L-
18F-
FMAC and L-
18F-FAC exhibited a higher liver uptake than
18F-FAC. Splenic activity was highest for
18F-FAC,
whereas the uptake for the other probes was low. Muscle
uptake was higher for
18-FAC than for the L-enantiomers.
The SUV averaged over three volunteers is displayed in
Fig. 3 for several organs. The SUV for L-
18F-FMAC and
L-
18F-FAC remained relatively stable during the observation
period of about 100 min except for the myocardium and
kidneys. In contrast,
18F-FAC SUVs decreased in spleen and
liver while muscle uptake increased slightly over time.
Discussion
The synthesis of
18F-FAC, a deoxycytidine analog, was
described previously [7, 8]. This probe is phosphorylated
and trapped in tissues by dCK, a rate-limiting enzyme in
the deoxyribonucleoside salvage pathway.
18F-FAC shares
a common biochemical pathway with a class of nucleoside
prodrugs widely used in cancer therapy (Fig. 1). Both the
imaging probe and these prodrugs are transported into the
cells via equilibrative nucleoside transporters and are
phosphorylated by dCK. The phosphorylation step is
prerequisite to convert the inactive prodrugs into their
active forms (reviewed in [6]).
The common metabolic fate of the probe and of the
prodrugs suggests that
18F - F A Cc o u l db eu s e dt op r e d i c t
treatment response. This was demonstrated in murine tumor
models [8]. We found that
18F-FAC accumulation was
specific for dCK-positive tumors. Moreover, only the dCK-
positive/
18F-FAC-positive but not the dCK-negative/
18F-FAC-
negative tumors responded to gemcitabine treatment [8].
However, several of the dCK-dependent prodrugs (Fig. 1b)
are deaminated by CDA to analogs that are not substrates for
dCK, and therefore are pharmacologically inactive. Analo-
gous to these prodrugs,
18F-FAC is also deaminated, and this
may decrease the amount of probe that can be trapped in
dCK-expressing cells. Deamination could also increase
background activity by producing
18F-FAU, a radiolabeled
metabolite of
18F-FAC, in a dCK-independent manner.
On the prodrug side, the deamination issue has been
solved by developing deamination-resistant purine analogs
such as cladribine and clofarabine [22]. Since clofarabine is
Organ
18F-FAC L-
18F-FAC L-
18F-FMAC
Heart 0.0117±0.0010 0.0079±0.0019 0.0080±0.0007
Kidneys 0.0240±0.0033 0.0166±0.0019 0.0126±0.0043
Liver 0.0603±0.0060 0.1659±0.0454 0.1449±0.0295
Marrow 0.0235±0.0056 0.0328±0.0047 0.0232±0.0023
Muscle 0.4083±0.1002 0.2314±0.0043 0.2521±0.0199
Salivary glands 0.0035±0.0009 0.0029±0.0008 0.0029±0.0006
Spleen 0.0103±0.0012 0.0052±0.0030 0.0038±0.0004
Urinary bladder 0.0325±0.0047 0.0705±0.0104 0.1084±0.0121
Remainder 0.2787±0.1230 0.3365±0.2023 0.4000±0.1269
Table 2 Residence time τ in
hours. Mean±1 SD of three
volunteers per probe
Table 3 Highest individual absorbed dose per probe
Type Organ
18F-FAC Organ L-
18F-FAC Organ L-
18F-FMAC Units
Volunteer
Critical Bladder 2.48E-02 Bladder 6.19E-02 Bladder 6.64E-02 mGy/MBq
2nd highest Spleen 1.93E-02 Liver 4.31E-02 Liver 2.45E-02 mGy/MBq
3rd highest Kidneys 1.86E-02 Kidneys 1.74E-02 Kidneys 1.67E-02 mGy/MBq
Patient
Lymphoma Bladder 6.4 mGy
E 2.2 mSv
Ovarian cancer Bladder 20.2
a mGy
E 3.4
a mSv
E effective dose
aPET/CT study for which the RDRC and IRB have approved 370 MBq maximum administered activity
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18F labeling, in theory,
18F-clofarabine could
represent the solution to the deamination problem. However,
we synthesized
18F-clofarabine and found that this probe
lacks the necessary specificity to image dCK-positive tissues
in mice [11]. Therefore, we developed an alternative strategy
to identify dCK substrates that are resistant to deamination.
We took advantage of a special property of dCK. Unlike
most enzymes, dCK lacks stereospecificity and acts on both
natural (D-) and non-natural (L-) enantiomers of all its
substrates [13]. In contrast, CDA is stereospecific and its
affinity for non-natural nucleoside is greatly reduced [13].
Thus, we developed a series of L-enantiomers of
18F-FAC for
PET imaging of dCK activity. The radiochemical synthesis,
biochemical evaluation, and biodistribution in mice of these
new PET probes are described elsewhere [11].
Human biodistribution
Here we compared the biodistribution in humans of a D-
enantiomer (
18F-FAC) and two L-enantiomers (L-
18F-FAC
and L-
18F-FMAC). Based on the known pattern of dCK
expression in tissues (reviewed in [3]) we expected these
probes to show high uptake in hematopoietic/lymphoid
tissues such as bone marrow and thymus.
The enzymatic activity of CDA, which is likely to affect
the biodistribution of the radiolabeled D-enantiomers, also
varies substantially among different species and organs [12].
In general, humans have more deamination activity than
mice, while rats almost completely lack CDA activity. For
instance, the ratio of dCK to CDA in murine splenic tissues
is around 4:1, while it is 1:20 in the liver. In contrast, the
Target organ
18F-FAC L-
18F-FAC L-
18F-FMAC
Adrenals 4.49E-03±8.96E-04 6.09E-03±1.70E-03 4.91E-03±8.64E-04
Brain 2.00E-03±7.59E-04 2.49E-03±1.34E-03 2.44E-03±7.00E-04
Breasts 2.23E-03±6.41E-04 2.82E-03±1.18E-03 2.53E-03±6.27E-04
Gallbladder wall 4.68E-03±7.79E-04 7.57E-03±2.07E-03 6.31E-03±1.22E-03
LLI wall 3.94E-03±8.05E-04 4.97E-03±1.58E-03 4.88E-03±8.43E-04
Small intestine 3.71E-03±8.00E-04 4.51E-03±1.47E-03 4.42E-03±8.93E-04
Stomach wall 3.72E-03±7.90E-04 4.47E-03±1.48E-03 3.86E-03±8.09E-04
ULI wall 3.76E-03±8.57E-04 4.91E-03±1.69E-03 4.42E-03±9.02E-04
Heart wall 9.71E-03±1.71E-03 9.12E-03±2.31E-03 7.27E-03±9.02E-04
Kidneys 1.77E-02±3.00E-03 1.45E-02±2.06E-03 1.07E-02±2.14E-03
Liver 9.96E-03±1.37E-03 2.84E-02±7.59E-03 1.93E-02±3.82E-03
Lungs 3.19E-03±7.40E-04 4.22E-03±1.40E-03 3.44E-03±7.41E-04
Muscle 4.83E-03±2.87E-04 4.72E-03±7.19E-04 3.84E-03±4.40E-04
Ovaries 4.09E-03±8.02E-04 5.11E-03±1.54E-03 4.96E-03±8.62E-04
Pancreas 4.59E-03±8.66E-04 5.88E-03±1.64E-03 4.86E-03±9.13E-04
Red marrow 4.56E-03±8.63E-04 5.61E-03±1.49E-03 4.86E-03±6.15E-04
Osteogenic cells 4.91E-03±1.49E-03 6.46E-03±2.32E-03 5.18E-03±1.03E-03
Skin 2.14E-03±5.01E-04 2.52E-03±9.91E-04 2.33E-03±5.20E-04
Spleen 1.37E-02±1.25E-03 9.24E-03±2.92E-03 6.21E-03±5.37E-04
Testes 2.83E-03±7.42E-04
a 3.64E-03±6.75E-04
Thymus 3.19E-03±6.81E-04 3.60E-03±1.36E-03 3.15E-03±6.87E-04
Thyroid 2.86E-03±5.40E-04 2.90E-03±1.20E-03 2.88E-03±6.49E-04
Urinary bladder wall 2.04E-02±3.95E-03 4.96E-02±7.22E-03 5.43E-02±6.03E-03
Uterus 4.59E-03±8.60E-04 6.28E-03±1.60E-03 6.77E-03±1.01E-03
Total body 4.20E-03±5.92E-04 4.97E-03±1.39E-03 4.32E-03±7.35E-04
Table 4 Absorbed dose in
mGy/MBq, three volunteers per
probe, mean±1 SD
LLI lower large intestine, ULI
upper large intestine
aThe volunteers for L-
18F-FAC
were all female
Type Gender
18F-FAC Gender L-
18F-FAC Gender L-
18F-FMAC
Volunteer 1 M 4.04E-03 F 9.69E-03 M 8.18E-03
Volunteer 2 M 5.54E-03 F 8.80E-03 M 6.40E-03
Volunteer 3 F 5.70E-03 F 6.14E-03 M 8.28E-03
Reference person 5.24E-03 7.55E-03 9.10E-03
Table 5 Effective dose in mSv/
MBq
Eur J Nucl Med Mol Imaging (2011) 38:711–721 717ratio is around 1:20 in the human spleen and 1:200 in the
human liver. Human bone marrow has very high CDA
enzymatic activity, while this enzyme is essentially unde-
tectable in the murine marrow [12].
None of the three PET probes showed thymic retention in
our volunteers, which is not surprising since the involution
of the thymus starts around puberty and is nearly complete
by 30 years of age [23]. Future studies in patients with
rebound thymic hyperplasia following chemotherapy will
examine whether the thymus can be visualized using PET
with fluorinated deoxycytidine analogs.
Bone marrow was well visualized with L-
18F-FAC and
L-
18F-FMAC but less well with
18F-FAC. The most likely
explanation is that in humans
18F-FAC undergoes exten-
sive deamination in the blood and other organs and this
significantly decreases the amount of probe available for
trapping in bone marrow cells [12]. In contrast, splenic
uptake was high for
18F-FAC but at background levels for
the L-enantiomers. Spleen and liver showed a significant
decrease in activity for
18F-FAC; the other organs did not
show a significant change over the 100-min imaging
period. This resulted in biological half-lives exceeding the
physical half-life of
18F( T a b l e1). PET imaging of dCK
activity can be performed as early as 20 min after tracer
injection.
High CDA levels are found in the human spleen and the
splenic activity might therefore represent unspecific
18F-
FAU (the product of CDA-catalyzed deamination of
18F-
FAC) [12]. As shown in Fig. 3, the SUV of
18F-FAC
decreased over time and slopes of tracer clearance from the
spleen resembled those from the kidneys. This suggests that
the
18F-FAC uptake in the spleen may not be dCK specific
and that the high initial uptake might be explained by the
high blood volume of this organ.
The D and L probes also differed in terms of liver uptake.
Hepatic activity was higher for L-enantiomers than for
18F-
FAC. Uptake remained high and actually increased slightly
during the imaging period (Fig. 3). In contrast, initial liver
uptake of
18F-FAC was about 60% lower and decreased
further with time. Preliminary data obtained using a dCK-
deficient mouse model [11] show a complete absence of
L-
18F-FAC liver uptake. In contrast, wild-type mice show
high liver uptake of L-
18F-FAC. These data suggest that, in
mice and possibly in humans, the liver uptake is dCK
specific. In this context, dCK is expressed in the human
liver, albeit at lower levels than in bone marrow and thymus
Fig. 3 Dynamic changes in probe uptake; average of three volunteers
per probe. Uptake is expressed as standardized uptake value
(SUVmean).
18F-FAC activity in liver and spleen decreased over time
while liver uptake of L-
18F-FAC and L-
18F-FMAC increased slightly.
Bone marrow uptake was lowest for
18F-FAC. Uptake is also noted in
salivary glands and muscles (most prominently for
18F-FAC)
Fig. 4
18F-FAC images obtained in a patient with diffuse large B-cell
lymphoma. The CT scan (left panel) shows extensive left axillary
lymphadenopathy (arrow). This corresponds to a region of increased
tracer uptake on the PET images suggesting that dCK expression of
this lesion is high. B bone marrow, Bl bladder, K kidney, L liver, LA
lymphadenopathy, M myocardium, S spleen. The scan was started
30 min after administration of 300 MBq of
18F-FAC. See Table 3 for
effective dose estimates
718 Eur J Nucl Med Mol Imaging (2011) 38:711–721[12]. The lower hepatic uptake and the rapid “washout” of
18F-FAC may be explained by differences in the transport
of the natural and non-natural nucleoside analogs in
hepatocytes.
Interestingly, the muscle uptake was markedly higher for
18F-FAC than for the two L-enantiomers. This resulted in
higher background activity for
18F-FAC. For instance, bone
marrow to muscle SUV ratio (muscle serving as back-
ground tissue) was close to 1 for
18F-FAC but ranged from
2t o3f o rL-
18F-FAC and L-
18F-FMAC. A potential
explanation for this observation is the rapid CDA-
mediated conversion of
18F-FAC to
18F-FAU. The biodis-
tribution of
18F-FAU in humans has been studied by Sun
and colleagues [24] who found that this PET probe has very
slow blood clearance and relatively high muscle retention.
The biodistribution in a patient is shown in Fig. 4 for
18F-FAC and in Fig. 5 for L-
18F-FMAC.
Radiation dosimetry
As shown in Tables 3, 4, and 5 the absorbed doses for the
three probes are acceptable and favorable for research and
clinical applications. For the two patients studied, the
absorbed dose estimate of the urinary bladder and the
effective dose are given in Table 3.
Assuming complete decay within the organs is conser-
vative, since radioactivity can be excreted by an organ or be
removed from the body altogether through the gastrointes-
tinal (GI) or genitourinary (GU) tract. Despite this overly
worst-case approach, the absorbed doses appeared to be
well within the required limits [21]. The absorbed dose to
the urinary bladder can be reduced significantly by frequent
voiding. For the probe with the highest absorbed dose in the
bladder, L-
18F-FMAC, the calculations were redone assum-
ing 50% voiding of bladder contents every 2 h. This means
that the effective half-life of tracer in the bladder is less
than 1 h. OLINDA/EXM estimates revealed that the
absorbed dose of the urinary bladder was reduced 15- to
24-fold, with a 7–22% decrease in the effective dose, E
[19]. More realistic scenarios will also include different
removal rates from certain organs (see Table 1) in addition
to urinary voiding. These “real life scenarios” will reduce
the absorbed dose even more, making the dosimetry of
18F-
labeled FAC probes more favorable than, for instance,
18F-
FDG with an effective dose of 1.9E-02 mSv/MBq (pp. 85–
87 of ICRP publication 106 [25]).
Administering a dose of 400 MBq of an
18F-labeled FAC
probe is thus warranted for human research (Tables 3 and
5). It should be kept in mind that the calculation method
used for patients in Table 3 is (unnecessarily) conservative.
In clinical practice, patients are asked to void before they
are positioned in the scanner. In addition, they are advised
to drink ample fluids and void frequently after the scan.
Thus, bladder emptying occurs and the actual absorbed
organ and body doses will, in reality, be lower than
estimated here.
Conclusion
The current studies confirm that
18F-FAC, L-
18F-FAC, and
L-
18F-FMAC have a favorable biodistribution in humans,
and further evaluation of these new PET probes is
warranted. Future studies will determine the ability of each
of these probes to detect tumor lesions that have upregu-
lated the dCK-dependent segment of the deoxyribonucleo-
side salvage pathway. The biodistribution of the D-
enantiomer
18F-FAC and the L-enantiomers L-
18F-FAC
Fig. 5 Selected axial slices of PET/CT fusion (a), CT (b), and PET
(c) obtained in a patient with metastatic ovarian cancer, demonstrating
L-
18F-FMAC uptake in a metastatic lesion located in the gastric
antrum. On PET/CT fusion images (a) physiologic uptake of L-
18F-
FMAC is seen in the liver (yellow arrow) and pancreas (blue arrow);
excreted L-
18F-FMAC is seen in both kidneys (white arrows).
Incidental note is made of a large right renal cyst (white arrowhead).
The scan was started 26 min after administration of 344 MBq of the
radiopharmaceutical. Table 3 provides absorbed dose estimates
Eur J Nucl Med Mol Imaging (2011) 38:711–721 719and L-
18F-FMAC showed considerable differences for
reasons which at this time are incompletely understood.
Given the metabolic fate of
18F-FAC, undergoing deami-
nation by CDA, the L-enantiomers appear to be more
promising for clinical use. Semiquantitative image analysis
revealed higher background activity for
18F-FAC than for
the L-forms (Fig. 3). This reduces target to background
ratios and henceforth image contrast. Despite its limited
metabolic stability,
18F-FAC might still be useful for
clinical studies because of its low liver uptake. The first
imaging study using
18F-FAC in a patient with diffuse large
B-cell lymphoma is depicted in Fig. 4. Increased tracer
uptake in a large left axillary lymph node conglomerate is
evident. Figure 5 shows the first patient study performed
with L-
18F-FMAC showing a gastric metastasis of an
ovarian cancer. Based on these promising results, we have
initiated PET imaging studies in patients with a variety of
solid tumors with the objective of identifying the most
sensitive and specific deoxycytidine analog for measuring
dCK activity in human cancers.
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